Seroprevalence of Hepatitis E Virus Infection and Factors Associated in HIV Infected Patients in Yaound&amp;#233; (Cameroon)

Ndam, Antonin Wilson Ndjitoyap; Njoya, O; Njouom, Richard; Kowo, Mathurin; Billong, Serge Clotaire; Andoulo, Firmin Ankouane; Njoya, Oudou; Ndam, Élie Claude Ndjitoyap

doi:10.4236/ojgas.2020.107018

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the overall IgM anti-HEV (11.7%) were similar to those described in Cameroon (12.2%) [27]. IgM seropositivity were 5.32% and 14.87% in pregnant women and blood donors respectively.…”

Section: Discussionsupporting

confidence: 85%

Seroprevalence of Hepatitis E Virus (HEV) Antibodies in Human Populations of Sokodé, Togo

Setondji¹,

Traoré²,

Ouoba³

et al. 2023

Arch Clin Biomed Res

View full text Add to dashboard Cite

Background: Hepatitis E virus (HEV) antibodies prevalence is reported globally worldwide. However, there is still some countries where data are not well reported or even studied as in Togo. The aim of this study was to evaluate the seroprevalence of HEV among human populations and analyze demographic variables related to the infection in the city of Sokodé, in central area of Togo.Results: A total of 289 individuals including 195 blood donors (24 women and 171 men), and 94 pregnant women were recruited from May to October 2020 and socio-economic status were assessed. All obtained sera were tested for the presence of anti-HEV antibodies with the immunochromatography test (MP Diagnostics ASSURE IgM Rapid test) and the MP Diagnostics HEV-IgM and HEV-IgG ELISA. The association between anti-HEV status and potential risk factors was assessed. Total HEV antibodies were in 5.6% (95% CI: 3.8 -7.3%) of all samples. HEV IgM antibodies were detected in 11.7% (95% CI: 9.8-13.5%) of the samples, of which 29 (14.8%) were from the blood donors group and 5 (5.3%) from pregnant women group. Gender, water storage container, type of latrine used and washing hands after toilet were associated to anti-HEV IgM seropositivity in population. (p ≤ 0.05).Conclusion: These ndings from asymptomatic population suggest a probable HEV circulation at signi cant levels. These data are the rst step to understand the epidemiology of the HEV infection in Togo that deserved to be extended both in timing and Togo's region.

show abstract

Section: Discussionsupporting

confidence: 85%

Seroprevalence of Hepatitis E Virus (HEV) Antibodies in Human Populations of Sokodé, Togo

Setondji¹,

Traoré²,

Ouoba³

et al. 2023

Arch Clin Biomed Res

View full text Add to dashboard Cite

show abstract

In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus

Galani

Owona

Temdie

et al. 2021

In Silico Pharmacol.

View full text Add to dashboard Cite

Hepatitis E virus (HEV) infection is emerging in Cameroon and represents one of the most common causes of acute hepatitis and jaundice. Moreover, earlier reports showed evidence of falciparum malaria/HEVcoexistence. Although the Sofosbuvir/Ribavirin combination was recently proposed in the treatment of HEV-infected patients, no specific antiviral drug has been approved so far, thereby urging the search for new therapies. Fortunately, drug repurposing offers a good alternative to this end. In this study, we report the in silico and in vitro activities of 8 licensed antimalarial drugs and two anti-hepatitis C virus agents used as references (Sofosbuvir, and Ribavirin), for repurposing as antiviral inhibitors against HEV. Compounds were docked against five HEV-specific targets including the Zinc-binding non-structural protein (6NU9), RNA-dependent RNA polymerase (RdRp), cryoEM structure of HEV VLP, genotype 1 (6LAT), capsid protein ORF-2, genotype 3 (2ZTN), and the E2s domain of genotype 1 (3GGQ) using the iGEMDOCK software and their pharmacokinetic profiles and toxicities were predicted using ADMETlab2.0. Their in vitro effects were also assessed on a gt 3 p6Gluc replicon system using the luciferase reporter assay. The docking results showed that Sofosbuvir had the best binding affinities with 6NU9 (− 98.22 kcal/mol), RdRp (− 113.86 kcal/mol), 2ZTN (− 106.96 kcal/mol), while Ribavirin better collided with 6LAT (− 99.33 kcal/mol). Interestingly, Lumefantrine showed the best affinity with 3GGQ (-106.05 kcal/mol). N -desethylamodiaquine and Amodiaquine presented higher binding scores with 6NU9 (− 93.5 and − 89.9 kcal/mol respectively vs − 80.83 kcal/mol), while Lumefantrine had the greatest energies with RdRp (− 102 vs − 84.58), and Pyrimethamine and N -desethylamodiaquine had stronger affinities with 2ZTN compared to Ribavirin (− 105.17 and − 102.65 kcal/mol vs − 96.04 kcal/mol). The biological screening demonstrated a significant ( P < 0.001) antiviral effect on replication with 1 µM N-desethylamodiaquine, the major metabolite of Amodiaquine. However, Lumefantrine showed no effect at the tested concentrations (1, 5, and 10 µM). The biocomputational analysis of the pharmacokinetic profile of both drugs revealed a low permeability of Lumefantrine and a specific inactivation by CYP3A2 which might partly contribute to the short half-time of this drug. In conclusion, Amodiaquine and Lumefantrine may be good antimalarial drug candidates for repurposing against HEV. Further in vitro and in vivo experiments are necessary to validate these predictions. Graphic abstract Supplementary Information The online version contains supplementary material available at 10.1007/s40203-021-00093-y.

show abstract

Seroprevalence of hepatitis E virus (HEV) antibodies in human populations of Sokodé, Togo

Setondji

Traoré

Ouoba

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Hepatitis E virus (HEV) antibodies prevalence is reported globally worldwide. However, there is still some countries where data are not well reported or even studied as in Togo. The aim of this study was to evaluate the seroprevalence of HEV among human populations and analyze demographic variables related to the infection in the city of Sokodé, in central area of Togo. Results: A total of 289 individuals including 195 blood donors (24 women and 171 men), and 94 pregnant women were recruited from May to October 2020 and socio-economic status were assessed. All obtained sera were tested for the presence of anti-HEV antibodies with the immunochromatography test (MP Diagnostics ASSURE IgM Rapid test) and the MP Diagnostics HEV-IgM and HEV-IgG ELISA. The association between anti-HEV status and potential risk factors was assessed. Total HEV antibodies were in 5.6% (95% CI: 3.8 - 7.3%) of all samples. HEV IgM antibodies were detected in 11.7% (95% CI: 9.8-13.5%) of the samples, of which 29 (14.8%) were from the blood donors group and 5 (5.3%) from pregnant women group. Gender, water storage container, type of latrine used and washing hands after toilet were associated to anti-HEV IgM seropositivity in population. (p ≤ 0.05).Conclusion: These findings from asymptomatic population suggest a probable HEV circulation at significant levels. These data are the first step to understand the epidemiology of the HEV infection in Togo that deserved to be extended both in timing and Togo’s region.

show abstract

Seroprevalence of Hepatitis E Virus Infection and Factors Associated in HIV Infected Patients in Yaoundé (Cameroon)

Cited by 3 publications

References 14 publications

Seroprevalence of Hepatitis E Virus (HEV) Antibodies in Human Populations of Sokodé, Togo

Seroprevalence of Hepatitis E Virus (HEV) Antibodies in Human Populations of Sokodé, Togo

In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus

Seroprevalence of hepatitis E virus (HEV) antibodies in human populations of Sokodé, Togo

Contact Info

Product

Resources

About